Ketamine-Buprenorphine Combo Sustains Anti-Suicidal Effects for Weeks, Study Finds

For decades, psychiatrists treating patients at imminent risk of suicide faced a cruel paradox. The interventions that work fastest—often providing relief within hours—fade before long-term treatments can take hold. Meanwhile, antidepressants and psychotherapy, while effective over time, require weeks to show meaningful benefit. In the gap between these two timelines, vulnerable patients sometimes slip through.

A study published May 18, 2026, in the American Journal of Psychiatry offers what researchers believe could be a bridge across that gap. A team led by Stanford Medicine investigators found that following a single ketamine infusion with four weeks of low-dose buprenorphine dramatically extends ketamine's rapid anti-suicidal effects, sustaining benefits for at least a month in adults with major depressive disorder.

The findings represent more than an incremental advance. They suggest the first pharmacological regimen capable of both rapid intervention and sustained protection against suicidal ideation—a combination that could reshape emergency psychiatric care.

The Speed-versus-Duration Dilemma

Ketamine's ability to quell suicidal thoughts within hours has been documented since the early 2000s. Unlike conventional antidepressants that modulate serotonin over weeks, ketamine works through the glutamate system, triggering rapid changes in synaptic connectivity. For patients in acute crisis, this speed can mean the difference between life and death.

But ketamine's benefits have always been ephemeral. The anti-suicidal effects typically begin fading within a week, sometimes sooner. Patients who experience dramatic relief on Monday may find themselves back in crisis by Friday, their window for engaging with longer-term treatments closed.

"These patients—some of whom have suffered chronically with the idea of dying, of self-harm—within a day get some relief," said Dr. Alan Schatzberg, the Kenneth T. Norris, Jr. Professor in Psychiatry and Behavioral Sciences at Stanford and senior author of the study. "But then what?"

The Stanford team set out to answer that question by testing whether buprenorphine, a medication best known for treating opioid use disorder, could serve as a pharmacological scaffold—supporting and extending ketamine's initial benefits while longer-term interventions take root.

A Randomized Trial with Striking Results

The study enrolled 50 adults with major depressive disorder and clinically significant suicidal ideation. All participants received a single open-label intravenous ketamine infusion. Two days later, once ketamine's acute effects had begun to manifest, researchers randomly assigned participants to receive either low-dose buprenorphine or placebo for four weeks.

Forty-five participants completed at least one week of follow-up treatment and were included in the primary analysis. Both groups improved, but the divergence between them grew steadily over time.

At the four-week mark, participants who received buprenorphine showed a 76% reduction in suicidal ideation scores compared to baseline. Those receiving placebo after ketamine showed a 43% reduction—a meaningful improvement, but substantially less robust.

The durability gap proved even more striking. At study's end, 78% of patients in the ketamine-buprenorphine group remained responsive to treatment, defined as having suicidal ideation scores cut by more than half. In the ketamine-placebo group, only 48% maintained that level of response.

On the Columbia Suicide Severity Rating Scale, which ranges up to 38 points, participants began the study with moderate severity scores averaging 15. After four weeks, the placebo group hovered at an average of 8.7—still above the clinical threshold of 6 that indicates significant risk. The buprenorphine group dropped to 3.6, well into the safety zone.

Separating Suicidality from Depression

Perhaps the most intriguing finding involved what the treatment did not do. While buprenorphine powerfully sustained ketamine's anti-suicidal effects, it did not significantly extend the drug's antidepressant benefits. Depression scores improved in both groups, but the difference between them failed to reach statistical significance.

This dissociation challenges long-held assumptions about the relationship between depression and suicidality. Clinically, the two conditions often travel together, and treatments that relieve major depression typically reduce suicide risk. But the Stanford findings suggest they possess distinct neurobiological substrates—at least pharmacologically.

"This proves that suicidality and depression possess separate underlying neurobiology," the researchers noted, a finding with profound implications for drug development. If suicidal ideation can be targeted independently of mood, pharmaceutical research could pursue more precise interventions for patients whose primary danger lies not in sadness but in the specific cognitive state of wanting to die.

The mechanism likely involves the endogenous opioid system. A 2018 Stanford study demonstrated that blocking opioid receptors eliminates ketamine's therapeutic benefits, suggesting the drug works partly by activating natural opioid networks in the brain. Buprenorphine, as a partial opioid agonist, may reinforce and prolong this activation without producing the full euphoric effects that drive addiction.

From Research to Clinical Practice

Both ketamine and buprenorphine are already FDA-approved medications with established safety profiles. Ketamine is widely used as an anesthetic, while buprenorphine has been a cornerstone of opioid use disorder treatment for nearly two decades. Neither is currently approved specifically for suicidal ideation, but both are available for off-label use by qualified prescribers.

This existing regulatory status means the ketamine-buprenorphine sequence could be adopted relatively quickly if the findings hold up in larger trials. "We have a sequence of treatments that's doable now if the field wants to adopt it," Schatzberg said.

The extended reprieve provided by the combination—buying patients four weeks or more of reduced suicidal thinking—could prove transformative for clinical workflows. During that window, patients have time for antidepressants to take effect, for therapeutic relationships to develop, for social services to be arranged. The treatment doesn't replace longer-term interventions; it creates space for them to work.

Dr. Christine Yu Moutier, chief medical officer of the American Foundation for Suicide Prevention, which funded the research, emphasized the study's significance for a field that has seen frustratingly few pharmacological advances. "One of the first to show the effectiveness of a pharmacologic intervention in helping maintain and build on ketamine's anti-suicidal effects in an at-risk population," she called it.

Limitations and Open Questions

The study's authors acknowledge important caveats. The trial was relatively small, and participants were carefully selected—excluded if they had substance use disorders, active psychosis, or certain medical conditions. Whether the findings generalize to broader populations, including those with co-occurring addiction, remains unknown.

The optimal duration of buprenorphine treatment also requires clarification. The study used a four-week course, but some patients may need longer maintenance while others might taper sooner. Discontinuation strategies, relapse prevention, and long-term safety all need further investigation.

Additionally, the study focused on suicidal ideation rather than suicide attempts or completed suicides. While reducing ideation is clinically meaningful, demonstrating an impact on actual behavior would require larger, longer trials with different endpoints.

Implications for Addiction Treatment

Though the study excluded participants with substance use disorders, its findings carry relevance for addiction medicine. Buprenorphine's central role in the protocol highlights the medication's versatility beyond opioid use disorder. Its partial agonist properties—activating opioid receptors enough to provide therapeutic benefit without producing full euphoria—may prove valuable in treating various psychiatric conditions characterized by dysregulated reward processing.

The research also underscores growing recognition of the opioid system's involvement in mood regulation and suicidal behavior. This understanding could inform development of new pharmacological approaches that target specific receptor subtypes while minimizing addiction risk.

For patients with co-occurring depression and substance use disorders—an enormous and underserved population—the ketamine-buprenorphine combination may eventually offer dual benefits. Future research specifically in this population could determine whether the sequence addresses both conditions simultaneously.

A Field in Transition

The Stanford study arrives amid a period of unusual ferment in psychiatric pharmacology. After decades dominated by serotonin-focused antidepressants, researchers are exploring novel mechanisms including glutamate modulation, psychedelic-assisted therapy, and now opioid system targeting. The FDA has granted breakthrough therapy designations to psilocybin and MDMA for treatment-resistant depression and PTSD, with approvals potentially coming later this year.

Against this backdrop, the ketamine-buprenorphine combination offers something distinct: not a new compound requiring years of regulatory review, but a new sequence using drugs already available. If replicated and refined, it could provide immediate benefit while more experimental therapies work through the approval pipeline.

For the estimated 12 million American adults who experience serious suicidal ideation annually, and for the clinicians struggling to keep them safe, that immediacy matters. The gap between crisis and effective treatment has always been measured in days. This research suggests it may finally be possible to close it.